By Kathryn Hardison
Vallon Pharmaceuticals Inc. agreed to merge with GRI Bio Inc., a privately-held biotech, in an all-stock deal. The combined company will focus on T cell regulators for the treatment of inflammatory, fibrotic and autoimmune diseases. Vallon shares surged 154% in after-hours trading on Tuesday.
Icosavax Inc. said new data from a trial of its IVX-121 vaccine has demonstrated a sustained neutralizing antibody response against the respiratory syncytial virus, lasting for at least six months after a single dose. Shares rallied 11% in after-hours trading.
Kaspien Holdings Inc. posted a wider third-quarter loss and lower revenue. The e-commerce marketplace's revenue fell to $29.1 million, which the company said was due to declines in fulfillment by Amazon.com Inc. in the U.S. Shares dropped 29% in after-hours trading, reversing course after the stock gained 35% during the day.
Write to Kathryn Hardison at kathryn.hardison@wsj.com
(END) Dow Jones Newswires
December 13, 2022 18:23 ET (23:23 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Comments